CV risk reduction beyond statin therapy: Exploring the role of icosapent ethyl
In this series of videos, three lipids experts discuss the following topics: residual CV risk, findings of CV outcome trials with icosapent ethyl and potential mechanism of benefit with icosapent ethyl.
Episodes 1-4 of 4
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylPotential mechanisms of benefit of icosapent ethyl
Prof. Chris Packard, PhD
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylDiscussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl
Prof. Ulrich Laufs, MD, PhD
prof. Chris Packard, PhD prof. Wouter Jukema, MD, PhD
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylExploring the role of icosapent ethyl based on current clinical evidence
Prof. Wouter Jukema, MD, PhD
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylResidual CV risk in patients on statin therapy
Prof. Alberto Zambon, MD, PhD
